Inhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury
NCT06819462
Cross Infection, Disease Attributes
Nanjing, Jiangsu, China
View Trial DetailsNCT Number: NCT07129174
After neurosurgery, many patients need to stay in the intensive care unit (ICU) and use a breathing machine (mechanical ventilation) because of issues like decreased consciousness, weak breathing, or poor airway protection. During this period, the natural balance of bacteria in the lungs-known as the lung microbiota-can be disturbed by surgery, antibiotics, and airway procedures. This may reduce healthy bacteria and allow harmful bacteria to grow, increasing the risk of lung infections such as ventilator-associated pneumonia (VAP).
This study will follow 220 postoperative neurosurgical ICU patients at three centers: Beijing Tiantan Hospital, Beijing Shijitan Hospital, and Beijing Anzhen Hospital from August 2025 to August 2026. These patients will include those undergoing surgery for brain tumors, brain hemorrhage, or traumatic brain injury. Airway secretion samples (tracheal aspirates) will be collected shortly after surgery and at several subsequent time points to assess how lung bacteria change over time while patients are using a breathing machine.
Using advanced laboratory methods, the investigators will measure both the amount and types of bacteria in the lungs. The aim is to determine how these changes are related to patient outcomes, such as the occurrence of lung infections.
The results of this study may contribute to earlier detection of lung infections and the development of personalized treatment plans to improve recovery in ICU patients after neurosurgery.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Postoperative neurosurgical patients represent a unique and high-risk population in the ICU, often requiring prolonged invasive mechanical ventilation due to impaired consciousness and respiratory function. During this critical period, multiple factors-including surgical trauma, antibiotic administration, and airway manipulation-can disrupt the pulmonary microbiota, potentially leading to dysbiosis characterized by reduced microbial diversity and overgrowth of opportunistic pathogens.
Emerging evidence suggests that alterations in the lung microbiota may play a key role in the development of respiratory infections, such as ventilator-associated pneumonia (VAP), and could influence the overall clinical trajectory of ICU patients. However, current knowledge regarding the temporal dynamics of the lung microbiome in neurosurgical patients is limited, and its potential as a predictive biomarker for infection risk or recovery remains unexplored.
This prospective observational cohort study is designed to systematically characterize the succession patterns of the pulmonary microbiota in adult neurosurgical patients requiring mechanical ventilation. By integrating microbial profiling with clinical data, the study aims to elucidate the relationship between microbiota changes and patient outcomes, including infection incidence, length of ICU stay, and duration of ventilation.
High-resolution microbial analysis using 16S rRNA gene sequencing and quantitative techniques (e.g., droplet digital PCR) will allow for precise tracking of microbial shifts over time. These findings may provide new perspectives on host-microbiota interactions under ICU conditions and support the development of early warning indicators for infection, as well as inform personalized antimicrobial and ventilation strategies in postoperative care.
Ultimately, the study seeks to improve understanding of lung microbiome evolution in response to surgical and critical care interventions and to identify clinically relevant microbial patterns that may serve as novel prognostic tools in neurosurgical ICU populations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Within 28 days of ICU admission
Hospital-acquired pneumonia (HAP) will be diagnosed according to the 2016 IDSA/ATS guidelines. The number of HAP cases occurring within 28 days of ICU admission will be recorded. This outcome will be used to evaluate whether alterations in the pulmonary microbiota are associated with the risk of nosocomial pneumonia and may inform empiric antibiotic strategies in the ICU setting.
Time frame: Within 28 days of ICU admission
Changes in pulmonary microbiota composition and diversity, assessed using 16S rRNA gene sequencing and quantitative analysis, will be evaluated for their association with the occurrence of hospital-acquired pneumonia (HAP) during the ICU stay. Statistical models will be applied to determine correlations between microbiota alterations and HAP risk.
Time frame: Within 28 days of ICU admission
Ventilator-associated pneumonia (VAP) will be diagnosed according to the 2016 IDSA/ATS guidelines as pneumonia occurring 48 hours or more after endotracheal intubation or tracheostomy. The number and proportion of VAP cases occurring within 28 days of ICU admission will be calculated.
Time frame: Within 28 days of ICU admission
Changes in pulmonary microbiota composition and diversity, assessed using 16S rRNA gene sequencing and quantitative analysis, will be evaluated for their association with the occurrence of ventilator-associated pneumonia (VAP) during the ICU stay. Statistical models will be applied to determine correlations between microbiota alterations and VAP risk.
Contact information is provided by the study sponsor or research team.
Jian-Xin Zhou, Professor
CONTACT
Yi-Ran Li, MD
CONTACT
Jian-Xin Zhou
Other
Association Between Changes in Pulmonary Microbiota and Clinical Outcomes in Neurosurgical ICU Patients With Artificial Airways: A Prospective Observational Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06819462
Cross Infection, Disease Attributes
Nanjing, Jiangsu, China
View Trial DetailsNCT06743529
Cross Infection, Disease Attributes
Angers, France
View Trial DetailsNCT06834971
Cross Infection, Disease Attributes
Jinan, Shandong, China
View Trial DetailsNCT07268560
Complicated Intra-Abdominal Infections, cIAIs, Cross Infection
Nanchang, Jiangxi, China
View Trial Details